What SEC filings does VivoSim Labs, Inc. submit to the SEC?

VivoSim Labs, Inc. (VIVS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about VIVS?

A Form 4 for VIVS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from VivoSim Labs, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for VIVS?

The 10-K is VivoSim Labs, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all VIVS SEC filings directly on EDGAR?

You can view all historical VivoSim Labs, Inc. filings on the SEC EDGAR company page for VIVS. Each filing card on this page links directly to the original SEC document.

How often does VivoSim Labs, Inc. file with the SEC?

VivoSim Labs, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling VIVS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

VIVS SEC Filing News — VivoSim Labs, Inc.

Latest SEC filings for VivoSim Labs, Inc. (VIVS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic c…

Sector: Healthcare Industry: Biotechnology Market Cap: $2.6M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by VivoSim Labs, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

VIVS Filing Activity Snapshot 2025-11-19 — 2026-10-16

Insider Transactions (Form 4)

1 buy vs 1 sell

Insider buying and selling activity is balanced in this period.

Largest Form 144 Filing

$7.3K

Gobel David (Director) · 2025-11-19

3,266 shares · Form 4

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for VivoSim Labs, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 compensation award, 1 open-market purchase and 1 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×6: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market purchase Insider Buying 2026-09-01

VIVS insider Lialin Tony Serge (Chief Commercial Officer) bought 10,000 shares (~$2.8K)

Lialin Tony Serge, listed as Chief Commercial Officer at VivoSim Labs, INC., reported an open-market purchase of 10,000 VIVS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$0.28	$2.8K

Filing: Form 4 (Insider Transaction) Insider: Lialin Tony Serge (Chief Commercial Officer) Shares: 10,000 Est. Value: $2.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-29

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

Cohen Douglas Jay (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Cohen Douglas Jay (Director) Shares: 15,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-29

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

Murphy Keith (Director, EXECUTIVE CHAIRMAN) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Murphy Keith (Director, EXECUTIVE CHAIRMAN) Shares: 15,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-29

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

Milhous Alison Tjosvold (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Milhous Alison Tjosvold (Director) Shares: 15,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-29

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

Gobel David (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Gobel David (Director) Shares: 15,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-01-29

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

STERN ADAM K (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: STERN ADAM K (Director) Shares: 15,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2025-11-26

VIVS insider Form 4 filed for equity award, exercise, or tax withholding

Sethi Amar Akhtar (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Options (right to buy)	53,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Sethi Amar Akhtar (Chief Scientific Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2025-11-19

VIVS insider Gobel David (Director) sold 3,266 shares (~$7.3K)

Gobel David, listed as Director at VivoSim Labs, INC., reported an open-market sale of 3,266 VIVS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,266	$2.24	$7.3K

Filing: Form 4 (Insider Transaction) Insider: Gobel David (Director) Shares: 3,266 Est. Value: $7.3K

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for VivoSim Labs, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-16